Drug and Substance Abuse in Refractory Epilepsy by The Pennsylvania State University CiteSeerX Archives
A.A. Ghanem et al. 
387 















Toxicology Lab, Emergency Hospital
3




Drugs and substances abuse in patients with refractor epilepsy were investigated in this study which includes 924 
patients with intractable epilepsy were studied for serum levels of antiepileptic drugs and for drugs and substances 
abuse. Positive results for abuse were detected in 246 patients (26.62%), 56.5% of them were in the age group 20 – 30 
years. Males outnumbered females with a sex ratio 1.46 : 1. Cannabis was the first abused drug as it was detected in 
29.27% followed by opiates in 21.95%, alcohol in 17.88%, benzodiazepine in 16.26%, tricylic in 8.54%, barbiturates in 
6.1%. So, a screening test for drugs and substances abuse must be done in cases with resistant epilepsy even if patients 





Seizures often occur in substance abusers. The 
mechanism may be indirect as a result of infection 
(particularly cerebral complications of endocarditis 
or AIDS in parenteral drug users), trauma (as a 
consequence of intoxication or of violence 
associated with drug use), stroke (hemorrhagic or 
ischemic), and metabolic derangement (including 
hyponatremia, hypocalcemia, renal failure and, 
particularly in alcoholics, hypoglycemia). Depending 
on the agent, direct mechanisms can be either 
intoxication or withdrawal in subjects physically 
dependent on a drug
1,2
. 
Due to the ever-increasing problem of drug 
abuse among young people and adolescents, the 
involvement of a drug should be suspected 
whenever there is a temporal relationship between 
the use of the drug and the onset of a neurological 
syndrome and when the other known risk factors 
have been excluded
3
. However, since addicts often 
use mixtures of drugs and do not give an honest 
report of their usage, it is difficult to assess the role 
of an individual drug
4
.   
The aim of the present work is to study the 
etiology of non-response to antiepileptic drugs by 
estimating their serum levels and screening of drugs 
and substance abuse in patients with resistant 
epilepsy. 
 
MATERIALS AND METHODS 
 
This study was conducted in epilepsy out 
patient clinic, Neurology Department, Mansoura 
University Hospital, between January 2005 and 
December 2007.  
After exclusion of those with symptomatic 
epilepsy or non compliance to treatment or with 
epilepsy other than generalized tonic-clonic seizures, 
924 patients with resistant epilepsy were included.   
 
They were subjected to:  
 Toxicology screen for detection of drug and 
substance abuse by analysis of urine and blood 
samples. 
 Measurements of the level of antiepileptic 
drugs in the blood (carbamazepine, valproic 
acid, phenytoin). 
 
These were done by EMIT (Enzyme Multiplied 
Immunoassay Test) system. 
 
Instrument:  
Syva Solaris System, an automated drug 
analyzer designed to work with the Syva Emit assay 
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tests.  The cut off concentration of abused drugs and 
substances tested was opiates (300 ng/ml), 
barbiturates (200 ng/ml), benzodiazepines (200 
ng/ml) and cannabinoids (50 ng/ml), tricyclic 
antidepressants (300 ng/ml) and alcohol (positive or 
negative at any concentration). All assays run on the 




Positive results for drug and substance abuse 
were found in 246 of 924 patients (26.62%). 
The age of patients ranged between 10 – 50y 
with a mean age 23.74  6.51 years.  56.5% of them 
were in the age group 20 – 30 years, followed by 
those aged 30 – 40 years (26.02%). Adolescents (10 
– 20) years accounted for 10.98% of the patients.  
As regards sex, the present study revealed that males 
outnumbered females (59.35% and 40.65% 
respectively) with a sex ratio 1.46 : 1 (Table 1). 
Cannabis was the first abused drug (29.27%), 
opiates was the second drug abused by patients 
(21.95%) followed by alcohol (17.88%), 
benzodiazepine (16.26%) tricyclic antidepressants 
(8.54%) and finally barbiturate constituted (6.1%) 
(Table 2).  
The study showed that in males the most 
common abused substance was cannabis (33.56%) 
followed by alcohol (30.14%) then opiates (21.23%) 
and benzodiazepines (6.85%), both tricyclic and 
barbiturates (4.1%), while the most of females were 
likely to abuse benzodiazepines (30%), the 
remaining abused; cannabis (23%), opiates (23%), 
tricyclic (15%) and barbiturates (9%) (Table 3). 
Table (4) showed the levels of carbamazepine, 
valproate and phenytoin assays for 115, 76 and 55 
patients respectively. Only 17 patients show serum 
level of antiepileptic drugs within therapeutic range, 
but 169 patients levels were below it and 60 patients 
with levels above it. 
 
 
Table 1. Demographic data of patients with drug and substance abuse.  
 
Age group 
Male Female Total 
No % No % No % 
10 – 20 
20 – 30 
30 – 40 

























Total 146 100.0 100 100.0 246 100.0 
 
 
Table 2. Type of drug and substance abuse in difference age group. 
 




10 – 20 20 – 30 30 – 40 40 – 50 
No % No % No % No % No % 
Cannabis 10 37.04 32 28.1 19 27.2 11 31.4 72 29.27 
Opiates 7 25.92 25 21.9 14 20 8 22.9 54 21.95 
Alcohol 3 11.11 21 18.4 13 18.6 7 20 44 17.88 
Benzodiazepines 3 11.11 18 15.8 14 20 5 14.3 40 16.26 
Tricyclic 2 7.41 10 8.8 5 7.1 4 11.4 21 8.54 
Barbiturates 2 7.41 8 7 5 7.1 - - 15 6.1 
Total 27 100 114 100 70 100 35 100 246 100 
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Table 3. Patients (n=246) with drug abuse and seizures by type of drug abuse and sex. 
 
Type of drug abuse overdose 
Males Females Total 
No % No % No % 
Cannabis 49 33.56 23 23 72 29.27 
Opiates 31 21.23 23 23 54 21.95 
Alcohol 44 30.14 - - 44 17.88 
Benzodiazepines 10 6.85 30 30 40 16.26 
Tricyclic 6 4.1 15 15 21 8.54 
Barbiturates 6 4.1 9 9 15 6.1 
Total 146 100 100 100 246 100 
 
 























Carbamazepine 59 5 13 77 30 3 5 38 115 
Valproic 23 1 10 34 15 7 20 42 76 
Phenytoin 30 - 5 35 12 1 7 20 55 





Recreational drug abusers are at increased risk 
for seizures by a variety of mechanisms
1,2
. Seizures 
precipitated by recreational drug abuse are usually 
caused by acute intoxication in contrast to the 




Drug abusers are prone to serious traumatic 
injuries
5




On the contrary, some reported that seizures 
are moderately infrequent complication of illicit 
drug use. In a prospective study, Alldredge et al.
7
 
reported recreational drug-induced seizures in 47 
patients among 186 000 inpatient admissions 
(0.025%) over a 12-year period. 
The process of addiction, after repeated 
administration of drugs involves alterations in the 




In this work toxicology screening for substance 
and drug abuse was done for 924 patients with 
resistant epilepsy (after exclusion those with organic 
brain lesion and who were not compliant to 
antiepileptic treatment).  Positive results were 
obtained in 246 patients (26.62%). 
The males out numbered females (59.35% & 
40.65% respectively) with a sex ratio of 1.46 : 1. 
The problem of drug abuse is increasing 
among young people and adolescence
3
. This study 
revealed that the highest age group of abuse was 
between 20 – 30 years (56.5%) followed by the age 
group 30 – 40 years (26.02%).  Teenagers represent 
10.98%. 
The risk of seizures increased in elderly 
people, probably owing to age-related reduction in 
metabolism and clearance that leads to drug 
accumulation, despite dosages well tolerated in 
younger patients
8
. Olson et al.
9
 reported that seizures 
in elderly patients were more likely to result in 
complication and death. 
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In the current study, it has been found that in 
males, abuse of cannabis was 33.56%, followed by 
alcohol 30.1%. In females benzodiazepines was the 
commonest (30%) followed by cannabis and opiates 
(23% for each). 
As regards type of seizure, our all patients 
suffered from generalized tonic-clonic seizures; 
however, focal and generalized seizures as well as 
status epilepticus have been described, but the 
seizures are usually of the generalized tonic-clonic 
variety and may follow ingestion, snorting, smoking 
or injection of a drug. It is important to note that the 
seizure problems related to recreational drug use are 
usually caused by acute intoxication, in contrast to 
the withdrawal seizures encountered in subjects who 
have been abusing alcohol, benzodiazepines or 
barbiturates. The pathophysiologic mechanism 
underlying seizures triggered during acute drug 
intoxication is unclear, but brain oedema has been 
suggested. Seizures frequently precede fatal 
intoxication, which implies that the patient should 
be treated immediately in an intensive care unit
3
. 
Marijuana use or withdrawal could potentially 
trigger seizures in susceptible patients
10
. In this study, 
cannabis was the most common abused drug in 
29.27% of patients (49 males, 23 females), 32 of them 
in the age group 20 – 30 years.  The mechanism by 
which marijuana affects seizures is not well defined. 
Dantas
11
 reported that in the general population the 
increased used of marijuana is influenced by gender 
(male), youth and unemployment. The relation 
between marijuana (cannabis sativa) and epilepsy is 
still controversial. In addition to reports supporting its 
anticonvulsant effects, a few reports support 
proconvulsant properties of marijuana, which may be 
related to withdrawal hyperexcitability
10,12,13
. This is 
very important issue because of ethical aspect as some 
of the components of cannabis have psychotropic 
effects
11
. Further study is needed to clarify these 
effects.  Experimental data, however, show that its 
principal psychoactive agent, 9-tetrahydrocannabiol, 
has serotonin-mediated anticonvulsant properties
14
.  
Another cannabinoid compound, cannbidiol, 
appears to be anticonvulsant in both animals and 
humans
2
.   
In the present study, 54 patients (21.95%) were 
opiate abusers (31 males and 23 females), they were 
mostly in the age group 20 – 30 years. Although 
opioid agonists lower seizure threshold in some 
animal models, seizures are an unusual feature of 
heroin or morphine overdose; their occurrence 
requires a search for another cause
15
. Except for 
neonatal withdrawal in cases of dependence 
developed in utero, seizures are not a feature of 
opiate withdrawal.  Most cases of seizures in opioid 
abuse, whether occurring acutely or during 
withdrawal, are probably due to secondary causes, 
including repeated self-injections with unsterile or 
embolic material or the use of additional agents such 
as cocaine or ethanol
16
. 
Also, Saboory et al.
17
 reported that high-dose 
opioid therapy can precipitate seizures; however, the 
mechanism of such a dangerous adverse effect 
remains poorly understood. However, they 
suggested that the proseizure effect of morphine is 
mediated through selective stimulation of mu and 
kappa opiate receptors but not the activation of the 
delta receptor system. 
Alcohol dependence is a widespread 




This study revealed that 44 patients (17.88%) 
abused alcohol, all were males. In a case-control 
study of 308 patients with seizures and 294 controls 
at Harlem Hospital in New York City, it was 
concluded that the total daily dose of ethanol, rather 
than the abrupt cessation of intake, was the principle 
risk factor for seizures. These investigators failed to 
demonstrate a clear-cut temporal relationship 
between seizures and early abstinence, with many 
seizures occurring during active drinking or more 
than a week after stopping. So the authors proposed 




The most serious risk of seizures in connection 
with alcohol use is withdrawal.  Alcohol withdrawal 
lowers the seizures threshold, an effect that may be 




Ethanol can also precipitate seizures in known 
epileptics, but the amount required is disputed
20
. 
Seizures usually occur in those who have abused 
alcohol for at least 10 years, and some studies found 
the risk of seizures to increase with repeated bouts 
of withdrawal, suggesting a kindling phenomenon
21
. 
It is important to recognize that alcohol 
predisposes to many medical and metabolic 
conditions that can mimic or cause seizures.  
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Hyponatremia and hypoglycemia associated with 
alcoholism can cause seizures
22
. 
The pathophysiology of ethanol-related seizure 
has not been fully elucidated. Ethanol acts at many 
levels of the neuroaxis, especially complex 
polysynaptic systems such as the reticular formation 
and parietal association cortex. It indirectly affects a 
number of neurotransmitter systems, especially 
glutamate and -aminobutyric acid (GABA), but also 
norepinephine, dopamine, serotonin, acetylcholine, 
and adenosine.  Ethanol binds to glutamate and 
GABA receptors, blocking glutaminergic 
neurotransmission and facilitating GABAergic 
neurotransmission. Up-regulation of glutamate re-
ceptors and down-regulation of GABA receptors 
then occurs; and when ethanol is removed, the result 
is an excitotoxic state, possibly accounting for 
seizures and delirium tremens. Repeated exposure 
might cause more lasting neuronal damage, 





 reported a significant 
increase in the high voltage activated calcium 
currents during the withdrawal period in the 
withdrawal seizure prone mouse strain, they 
suggested that an increase in calcium currents is one 
factor involved in the alcohol withdrawal 
hyperexcitability. 
In our study, 40 patients (16.26%) abused 
benzodiazepine and 15 patients (6.1%) abused 
barbiturates.  Benzodiazepines per se are relatively 
atoxic substances. In the central nervous system 
benzodiazepines bind to benzodiazepine receptors, 
which belong to the GABA-A receptor complex. 
This receptor is the most abundant inhibitory 
receptor in the mammalian brain
25
.  
Most of the benzodiazepines relieve anxiety 
and act as muscle relaxants. However, potentially 
life-threatening seizures may occur following the 
withdrawal of benzodiazepines and barbiturates. 
Drug addicts sometimes try to ameliorate their 
withdrawal symptoms or attenuate the side-effects of 
psychostimulants with benzodiazepines. 
Furthermore, drug abusers may also try to enhance 




Benzodiazepine withdrawal after long-term use 
is, at least in some cases, related to epileptic 
seizures. These fits are usually grand mal seizures
26
. 
The peak liability to seizures occurs between 5 and 7 
days after discontinuation of long-acting 
benzodiazepines and between 2 and 4 days after 
discontinuation of barbiturates, depending on the 
pharmcokinetic properties of the abused drug
27
. The 
pathophysiologic mechanisms underlying the 
transiently lowered seizure threshold shortly after 
the discontinuation of benzodiazepine and 
barbiturate abuse have been ascribed to several bio-
organic changes in the brain. These include effects 
of the drugs on both the GABA and glutamate 
receptor-mediated functions. In experimental 
animals, both diazepam and pentobarbital 




Because depression is common in the general 
population and occurs even more often in patients 
with epilepsy (up to 50%), and because treatment of 
depression usually requires long-term drug 
treatment, the choice of antidepressant medication 
must be made carefully, taking into account the 
possible effect on seizure threshold
29
.  
The occurrence of seizures was reported with 
cyclic antidepressants either by deliberate 
administration 
(30)
 or by poisoning
9, 31
. 
In this study, tricyclic antidepressants were 
detected in 15% of female and 4.1% of males and 
was common in age group 20 – 30 years. 
Olson et al.
9
 found that cyclic antidepressants 
poisoning was found in 29% of 191 cases of 
seizures with drug intoxication and reported that the 
seizures with cyclic antidepressants was more likely 
to be associated with death. Dailey and Naritoku
32
 
concluded that it is the antihistaminic, 
antimuscarinic, and local anaesthetic properties of 
antidepressants that are most likely responsible for 
any increased susceptibility to seizures. Even simple 
side effects of medication, however, such as 
drowsiness, can lower the seizure threshold in 
susceptible patients. 
As regard the increased seizure risk with 
antidepressant, the highest risk of seizures has been 
reported with the heterocyclic antidepressant, the 
dopamine- or norepinephrine-specific reuptake 
inhibitor bupropion and the quaternary antidepressant 
maprotiline. The tricyclic antidepressants (TCAs) have 
the next highest seizure risk (which is increased by 
toxic levels). The newer selective serotonin reuptake 
inhibitors (SSRIs) (fluoxetine, sertraline, 
fluvoxamine, citalopram, and paroxetine) and 
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serotonin receptor modulators (trazodone and 
nefazodone) are intermediate in risk, as is 
venlafaxine, a combined norepinephrine and 
serotonin reuptake inhibitor. The monoamine 
oxidase inhibitors (MAOIs) carry the least risk
33
. 
The risk of seizures in patients taking 
antidepressant drugs depends on three factors
32-35
. 
The intrinsic epileptogenic or antiepileptic potential 
of the antidepressant; the amount of active drug that 
enters the brain, which depends on the dose, 
pharmacokinetics, and transport across the blood-
brain barrier, the patient’s seizure threshold, which 
depends on genetic factors, remote brain injury, 
previous febrile or acute symptomatic seizures, and 
use of alcohol or other substances. 
The complex neurotransmitter effects of 
antidepressant drugs make it impossible to offer 
simplistic assumptions about their proconvulsant 
effects. Recent experimental studies of AEDs used 
to treat depression lead to the conclusion that it is 
unlikely that alterations in serotonin and 
norepinephrine levels are related to an increased risk 
of seizures
32





 may occasionally have 
anticonvulsants properties. 
Substance abuse may be the cause of resistant 
epilepsy as they are epileptogenic by themselves or 
due to drug-drug interaction with the antiepileptics. 
The study of serum antiepileptic levels in our 
patients showed that they were within therapeutic 
range only in 17 patients and were below in 169 
patients and above in 60 patients. 
Birkett et al.
37
 reported a 49-year-old female 
with chronic alcoholism and epilepsy, treated with 
phenytoin, began to convulse when treatment with 
disulfiram (an inhibitor of phenytoin metabolism) 
was discontinued. The patient at this stage was 
resistant to the large doses of phenytoin, apparently 
owing to induction of the metabolism of this drug by 
chronic alcohol intake. 
Reference to drug interaction charts is 
necessary to anticipate the effects of one drug on 
another, as there are several isoenzymes of both the 
CYP450 and GT systems. In general, antidepressant 
and antipsychotic drugs are metabolized by CYP2D6 
and CYP1A2, the enzyme systems that also 
metabolize carbamazepine. Most benzodiazepines 
and newer antipsychotic agents, as well as most 
other AEDs except phenytoin, use CYP3A4. 
Phenytoin and a few benzodiazepines use CYP2C9. 
Valproic acid is also metabolized by the glucuronyl 




When an AED is added to an antidepressant, 




antidepressants may trigger seizures in patients 
whose seizure threshold is lowered by drowsiness
32
.  
Enzyme-inhibiting antidepressant drugs, such 
as the SSRIs and TCAs, may require downward 
adjustment in the dosage of concurrently 
administered AEDs that are also metabolized by the 
cytochrome P-450 (CYP450) microsomal system in 
the liver. In other cases, phenytoin and 
carbamazepine inhibit the metabolism of 
antidepressant drugs, like fluoxetine or the TCAs, 






A screening test for drug and substance abuse 
is performed if drug abuse or withdrawal is 
suspected in patients with resistant epilepsy even if 
patient denies the use of them.   
To confirm the results of EMIT, further study 
is needed by using GCMS (gas chromatography 
mass spectrum) as it is more sensitive and more 
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اإلدمان فى الصرع الغير مستجيب للعالج 
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